Xu Shi-Lin, Tian Yu-Yang, Zhou Ying, Liu Li-Qiao
Department of Science and Technology, The Second Affiliated Hospital of Nanchang University, Nanchang, China.
Queen Mary School, Medical College, Nanchang University, Nanchang, China.
Clin Endocrinol (Oxf). 2020 Oct;93(4):489-498. doi: 10.1111/cen.14217. Epub 2020 May 26.
Thyroid cancer (TC) is the most common endocrine system tumour. Several studies had revealed the potential of circulating microRNAs (miRNAs) as novel biomarkers for the diagnosis of TC. The purpose of this meta-analysis is to summarize published studies and evaluate the diagnostic accuracy of circulating miRNAs in TC detection.
In this meta-analysis, we systematically searched three databases: PubMed, EMBASE and Cochrane Library. We used the bivariate mixed-effects regression model to calculate the pooled diagnostic parameters and conduct the summary receiver operator characteristic curve (SROC). All calculations were performed using stata software.
Thirty-five studies from 9 articles, including 663 TC patients, 519 patients with benign thyroid nodules (BTNs), and 84 healthy controls were included in this meta-analysis. The pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and area under the SROC curve (AUC) were 0.81 (95% CI 0.75-0.86), 0.81 (95% CI 0.75-0.86), 4.3 (95% CI 3.2-5.6), 0.24 (95% CI 0.18-0.31), 18 (95% CI 12-28) and 0.88 (95% CI 0.85-0.90), respectively in BTN controls, and 0.81 (95% CI 0.75-0.86), 0.85 (95% CI 0.75-0.91), 5.3 (95% CI 3.3-8.7), 0.23 (95% CI 0.18-0.29), 24 (95% CI 14-39), 0.89 (95% CI 0.86-0.91) in healthy controls. The subgroup analysis found that multiple miRNA assays had higher diagnostic accuracy than single miRNA assays with sensitivity of 0.88, specificity of 0.89 and AUC of 0.94.
Circulating miRNAs have good values to diagnose TC and distinguish TC patients from BTN patients. MiRNAs can assist in the diagnosis of malignancy and avoid unnecessary surgery. In summary, circulating miRNAs should be added to our current clinical tools.
甲状腺癌(TC)是最常见的内分泌系统肿瘤。多项研究揭示了循环微小RNA(miRNA)作为TC诊断新生物标志物的潜力。本荟萃分析的目的是总结已发表的研究,并评估循环miRNA在TC检测中的诊断准确性。
在本荟萃分析中,我们系统检索了三个数据库:PubMed、EMBASE和Cochrane图书馆。我们使用双变量混合效应回归模型计算合并诊断参数,并绘制汇总受试者工作特征曲线(SROC)。所有计算均使用Stata软件进行。
本荟萃分析纳入了9篇文章中的35项研究,包括663例TC患者、519例甲状腺良性结节(BTN)患者和84例健康对照。在以BTN为对照时,合并敏感性、特异性、阳性似然比(PLR)、阴性似然比(NLR)、诊断比值比(DOR)和SROC曲线下面积(AUC)分别为0.81(95%CI 0.75 - 0.8)、0.8(95%CI 0.75 - 0.86)、4.3(95%CI 3.2 - 5.6)、0.24(95%CI 0.18 - 0.31)、18(95%CI 12 - 28)和0.88(95%CI 0.85 - 0.90);在以健康对照时,分别为0.81(95%CI 0.75 - 0.86)、0.85(95%CI 0.75 - 0.91)、5.3(95%CI 3.3 - 8.7)、0.23(95%CI 0.18 - 0.29)、24(95%CI 14 - 39)和0.89(95%CI
0.86 - 0.91)。亚组分析发现,多种miRNA检测的诊断准确性高于单一miRNA检测,敏感性为0.88,特异性为0.89,AUC为0.94。
循环miRNA在诊断TC以及区分TC患者和BTN患者方面具有良好价值。miRNA可辅助恶性肿瘤诊断,避免不必要的手术。总之,循环miRNA应纳入我们当前的临床工具中。